BsUFA III Talks Could Move Cloud-Platform Goals Forward
Executive Summary
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
You may also be interested in...
New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting
Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.
New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting
Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.
Califf: More Learning Necessary During Generic Drug Lifecycle
The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.